INDIAGLYCO India Glycols Q3 FY25 results (Oct–Dec 2024) and concall
India Glycols reported a strong Q3 and 9M FY25 performance, driven by robust growth in Bio-Fuel and Potable Spirits segments. The company announced a strategic demerger into three separate listed entities to unlock value and provide focused growth. While Ennature Biopharma faced margin pressures, management outlined strategies for improvement, and the core chemicals business showed resilience despite reclassification impacts.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 961 | 975 |
| EBITDA | 116 | 124 |
| Net profit | 39 | 44 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
